Patients & CaregiversHealthcare Professionals - Opens new windowWorldwide - Opens new window
HomeAbout Merck Products NewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals


Merck Proxy Statement
Proposal
2003
Questions and Answers About the Annual Meeting and Voting
Questions and Answers About the Annual Meeting and Voting
Election of Directors
Security Ownership and Compensation
Performance Graph
Audit Committee
Ratification of Appointment of Independent Public Accountants
Adoption of the 2003 Incentive Stock Plan
Stockholder Proposals
Other Matters
Appendices
Proxy Home

5. Stockholder Proposal Concerning
    Director Nominees

Mr. Morris Scheffler, 59 Flower Road, Valley Stream, NY 11581, owner of 1,231 shares of Common Stock of the Company, has given notice that he intends to present for action at the Annual Meeting the following resolution:

"RESOLVED: That there be 2 nominees for each new member of the Board of Directors. That a brief resume of their background, experience and stockholdings in the Corporation be delineated. This should make the Board less beholden to the Management and more attuned to the needs of the owners, the employees and the customers of the corporation.

"REASONS: 'Corporate democracy' has become an oxymoron. 'Crony capitalism' is a more appropriate term. Directors are 'selected' by incumbent directors and management. Stockholders, the true owners of the corporation are allowed to vote for the directors anointed by the hierarchy. This is analogous to the 'free' elections in many dictatorships. You either voted for the dictator or did not vote. There was no alternative. In our 'corporate democracy' you either vote for, against or withhold your vote but there are no alternative directors to vote for. Corporate directors take office unopposed and answer only to fellow directors and not to the owners of the corporation, the stockholders."

Board of Directors' Statement in Opposition to the Resolution

The Board believes the proposal, which requires that the Company nominate two nominees for each new member of the Board, is not in the best interests of the Company or its stockholders.

The Board's Committee on Corporate Governance, which is comprised entirely of independent directors, acts as a screening and nominating committee for candidates to be considered for election to the Board. In this capacity, the Committee considers a nominee's depth of experience, balance of professional interests, required expertise and other factors. The Committee strives to obtain the single most qualified individual for each opening on the Board of Directors, taking into account the strengths and expertise of other Board members at the time. The Board believes that each candidate nominated for stockholder consideration is fully qualified to serve on the Board. Accordingly, the Board believes that doubling the number of candidates to be considered by the stockholders will simply make the process more time consuming and less efficient. It would not have a positive impact on the composition or independence of the Board and would likely result in confusion on the part of stockholders.

In addition, any stockholder who wishes to recommend a person as a director nominee may do so by contacting the Secretary of the Company. The process a stockholder must follow is set forth on pages 11-12 of this proxy statement, in the paragraph describing the Committee on Corporate Governance and its nominating function. Thus, stockholders have a clear opportunity to participate in the nomination of Board members.

The Board believes the Company's current nominating process has achieved a well balanced, diverse and independent Board of Directors, and the changes required by the proposal are unnecessary and not in the best interests of the Company or its stockholders.

The Board of Directors recommends a vote AGAINST this proposal.

Back to Stockholder Proposals Go to Stockholder Proposal Concerning Extension of Prescription Drug Patents


Contact Merck Site MapAccessibility StatementPrivacy PolicyTerms of UseCopyright 1995-2008 Merck & Co., Inc.